In the whole (CIS and MS) cohort, seven genes (HLA-DRB1*1501, AHI1, KCNIP1, IRX1, HDAC9, PVRL2 and EVI5) showed associations with outcomes measures assessed from 0 to 30 years using longitudinal mixed-effects models. Here, IRX1 is linked to in situ carcinoma.